» Articles » PMID: 36377432

Facile Synthesis of Weakly Ferromagnetic Organogadolinium Macrochelates-Based T -Weighted Magnetic Resonance Imaging Contrast Agents

Overview
Journal Adv Sci (Weinh)
Date 2022 Nov 15
PMID 36377432
Authors
Affiliations
Soon will be listed here.
Abstract

To surmount the major concerns of commercial small molecule Gd chelates and reported Gd-based contrast agents (GBCAs) for magnetic resonance imaging (MRI), a new concept of organogadolinium macrochelates (OGMCs) constructed from the coordination between Gd and macromolecules is proposed. A library of macromolecules were screened for Gd coordination, and two candidates [i.e., poly(acrylic acid) (PAA), and poly(aspartic acid) (PASP)] succeeded in OGMC formation. Under optimized synthesis conditions, both Gd-PAA12 and Gd-PASP11 OGMCs are outstanding T -weighted CAs owing to their super high r values (> 50 mm  s , 3.0 T) and ultralow r /r ratios (< 1.6, 3.0 T). The ferromagnetism of OGMCs is completely different from the paramagnetism of commercial and reported GBCAs. The ferromagnetism is very weak (M  < 1.0 emu g ) leading to a low r , which is preferred for T MRI. Gd is not released from the OGMC Gd-PAA12 and Gd-PASP11, ensuring biosafety for in vivo applications. The safety and T -weighted MRI efficiencies of the OGMC Gd-PAA12 and Gd-PASP11 are tested in cells and mice. The synthesis method of the OGMCs is facile and easy to be scaled up. Consequently, the OGMC Gd-PAA12 and Gd-PASP11 are superior T -weighted CAs with promising translatability to replace the commercial Gd chelates.

Citing Articles

A CIA strategy with eminent drug-loading capacities for tumor ferroptosis-gas synergistic therapy.

Zhu J, Huang L, Yang J, Li Z, Wu L, Xiong W Theranostics. 2024; 14(19):7349-7369.

PMID: 39659580 PMC: 11626936. DOI: 10.7150/thno.99295.


A Turbo-Charging System-Like Contrast Agent for MRI-Guided STING Pathway-Activated Cancer Immunotherapy.

Ren B, Yan S, Li Z, Huang Y, Cai H, Yang J Adv Sci (Weinh). 2024; 12(1):e2410432.

PMID: 39488791 PMC: 11714149. DOI: 10.1002/advs.202410432.


Advancements in Iron Oxide Nanoparticles for Multimodal Imaging and Tumor Theranostics.

Liu H, Zhen Z, Chen F, Chen J, Chen W Curr Med Chem. 2024; 32(2):301-321.

PMID: 39005127 DOI: 10.2174/0109298673301359240705063544.


A Hexanuclear Gadolinium(III)-Based Nanoprobe for Magnetic Resonance Imaging of Tumor Apoptosis.

Wu Y, Zhao S, Xu Y, Tang C, Feng Y, Zhang M ACS Appl Nano Mater. 2024; 7(8):9020-9030.

PMID: 38694722 PMC: 11059065. DOI: 10.1021/acsanm.4c00511.


Kilogram scale facile synthesis and systematic characterization of a Gd-macrochelate as T-weighted magnetic resonance imaging contrast agent.

Shi M, Xiong W, Feng J, Wu L, Yang J, Lu Y J Nanobiotechnology. 2024; 22(1):162.

PMID: 38594700 PMC: 11005285. DOI: 10.1186/s12951-024-02394-8.


References
1.
Li F, Liang Z, Liu J, Sun J, Hu X, Zhao M . Dynamically Reversible Iron Oxide Nanoparticle Assemblies for Targeted Amplification of T1-Weighted Magnetic Resonance Imaging of Tumors. Nano Lett. 2019; 19(7):4213-4220. DOI: 10.1021/acs.nanolett.8b04411. View

2.
Werner E, Datta A, Jocher C, Raymond K . High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging. Angew Chem Int Ed Engl. 2008; 47(45):8568-80. DOI: 10.1002/anie.200800212. View

3.
Ananta J, Godin B, Sethi R, Moriggi L, Liu X, Serda R . Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol. 2010; 5(11):815-21. PMC: 2974055. DOI: 10.1038/nnano.2010.203. View

4.
Zhang B, Cheng L, Duan B, Tang W, Yuan Y, Ding Y . Gadolinium complexes of diethylenetriamine-N-oxide pentaacetic acid-bisamide: a new class of highly stable MRI contrast agents with a hydration number of 3. Dalton Trans. 2019; 48(5):1693-1699. DOI: 10.1039/c8dt04478c. View

5.
Shin T, Kim P, Kang S, Cheong J, Kim S, Lim Y . High-resolution T MRI via renally clearable dextran nanoparticles with an iron oxide shell. Nat Biomed Eng. 2021; 5(3):252-263. DOI: 10.1038/s41551-021-00687-z. View